Most biotech companies in the world have pivoted to working on coronavirus. Failure to win in a year or two seems possible but failure to win over the course of a decade is much less likely, and wins could include safe genetic engineering solutions that cure both the common cold and HIV.
Most biotech companies in the world have pivoted to working on coronavirus. Failure to win in a year or two seems possible but failure to win over the course of a decade is much less likely, and wins could include safe genetic engineering solutions that cure both the common cold and HIV.